KDventures portfolio firm Umecrine Cognition wins US patent allowances for second-generation GAMSA compounds

PUBT · 1d ago
KDventures portfolio firm Umecrine Cognition wins US patent allowances for second-generation GAMSA compounds
  • KDventures reported portfolio company Umecrine Cognition received two USPTO Notices of Allowance for second-generation GAMSA compounds GR3053, GR3055.
  • Patents expected to provide US NCE protection until at least 2042, strengthening long-term IP coverage for the GAMSA platform.
  • Compounds target development in neurodegenerative diseases, expanding work beyond clinical candidate golexanolone.
  • Company cited preclinical signals in Parkinson’s disease-like models, with near-term focus on non-motor symptoms.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.